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Reliability of cystatin C in estimating
renal function in rugby players
Dear Sir,
Serum creatinine concentrations in professional athletes
are higher than those found in the general population, as
demonstrated in a large series of top-level sportsmen com-
peting in eight different sports disciplines.1 Cystatin C has
been proposed as an alternative to creatinine for assessing
glomerular ﬁltration rate (GFR).
We measured serum creatinine concentration in 25 men
(age range 22–30 years; mean body mass index [BMI] 27.4
(SD 1.3) kg/m2) belonging to the Italian national rugby
team; blood was drawn in January, in the middle of the
competitive season, when the psychophysical stress for ath-
letes is at highest level.
Serum creatinine was measured by the Jaffe reaction
(Aeroset c8000, Abbott, Chicago, IL, USA; upper limit of
normal 110 mmol/L) and by an enzymatic method
(Johnson and Johnson Vitros 950, Johnson and Johnson,
Raritan, NJ, USA). Cystatin C was measured nephelometri-
cally (Dade Behring, Marburg, Germany; upper limit of
normal 0.95 mg/L).
The mean Jaffe serum creatinine concentration was 115
mmol/L (SD: 13.3), while the mean value using the enzy-
matic method was 119 mmol/L (SD: 13.3). Twelve/ﬁfteen
players had serum creatinine concentrations exceeding
110 mmol/L using the Jaffe/enzymatic assays respectively.
The mean cystatin C concentration was 0.85 mg/L (SD:
0.08); no player had a cystatin C concentration exceeding
0.95 mg/L.
Body mass and in particular muscle mass are known to
inﬂuence serum creatinine concentration. Our data suggest
that serum cystatin C concentration may be a more accurate
reﬂection of GFR in these professional athletes.
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Dear Editor,
Heijboer et al.1 highlighted the potential interference in
the Roche free thyroxine (fT4) assay (Roche Diagnostics
GmbH, Mannheim, Germany) resulting from ruthenium
antibodies. Our laboratory performs approximately
100,000 thyroid proﬁles per annum. In 2005 we reported
to Roche our concerns regarding the high number of
increased fT4 results with normal thyroid-stimulating
hormone (TSH) concentrations we were observing in
euthyroid patients, with fT4 concentrations being normal
when repeated using an Auto Delﬁa assay (Wallac Oy,
Turku, Finland) in a neighbouring laboratory. In one case,
serum was referred to Roche for further investigation.
Roche reported fT4 concentrations of 17.1 and 24.3 pmol/
L with and without a blocking reagent, respectively, con-
ﬁrming the presence of interference against ruthenium.
Between 2005 and June 2007, we identiﬁed 11 cases of
falsely elevated fT4 concentrations in euthyroid patients.
Due to this, in collaboration with Roche, we installed the
TOSOH AIA360 analyser (Tosoh Corp., Tokyo, Japan) in
June 2007 to conﬁrm fT4 concentrations .22 pmol/L
locally. Between June 2007 and October 2008 (introduction
of lot 151161), we identiﬁed a further 33 fT4 results that
were signiﬁcantly elevated compared with the TOSOH
assay.
We posted our concerns regarding falsely raised fT4 con-
centrations on the ACB mail base in February 2007 (Inc
017967 and 017509 found at https://www.jiscmail.ac.uk/
cgi-bin/webadmin?A2=ind0702&L=ACB-CLIN-CHEM-GEN&
P=R20296) and were surprised that few other laboratories
seemed to be experiencing the same problem. Roche
responded to global customer complaints with the release,
in 2008, of a new generation of their fT4 assay with
reduced susceptibility to antiruthenium interference.
Subsequently, we have detected only one falsely increased
fT4. The sample in question came from a female patient
and was analysed during the period of evaluation of the
new generation fT4 assay. The fT4 results obtained by the
old generation (lot 150353) and new generation assays (lot
151161) were 42.6 and 40.3 pmol/L, respectively, with a
TSH of 1.28 mIU/L. Roche conﬁrmed these ﬁndings and
noted that lot 151161 resulted in only a slight decrease in
the measured fT4 concentration. Analysis with a research
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